Aerosolized active agent delivery

Abstract

The present invention is directed to methods and devices for delivering an active agent formulation to the lung of a human patient. The active agent formulation may be in dry powder form, it may be nebulized, or it may be in admixture with a propellant. The active agent formulation is delivered to a patient at an inspiratory flow rate of less than 17 liters per minute. The bioavailability of the active agent was found to increase at these flow rates when compared to inspiratory flow rates of 17 liters per minute or more.

1 - 22 . (cancelled)  
     
     
         23 . A device for increasing the bioavailability of an aerosolized active agent, said device comprising a flow restrictor for limiting the flow of an aerosolized active agent formulation to a human patient to less than 17 liters per minute, wherein the device is adapted to aerosolize the active agent formulation and wherein the active agent formulation is (i) a powder, (ii) a solution, suspension, or slurry that may be nebulized, or (iii) suspended or dissolved in a propellant.  
     
     
         24 . The device of  claim 23  wherein the flow restrictor comprises an orifice.  
     
     
         25 . The device of  claim 24  wherein the flow restictor comprises apertures of 0.5 to 0.9 mm in diameter.  
     
     
         26 . The device of  claim 23  wherein the flow restrictor is a valve that provides for decreasing resistance with increasing flow rate.  
     
     
         27 . The device of  claim 23  wherein the flow restictor is a valve that provides for high resistance at all flow rates except a desired flow rate range.  
     
     
         28 . The device of  claim 23  wherein the device is adapted to be used with an active agent selected from the group consisting of insulin, cyclosporin, parathyroid hormone, follicle stimulating hormone, alpha-1-antitrypsin, budesonide, human growth hormone, growth hormone releasing hormone, interferon alpha, interferon beta, growth colony stimulating factor, leutinizing hormone releasing hormone, calcitonin, low molecular weight heparin, somatostatin, respiratory syncytial virus antibody, erythropoietin, Factor VIII, Factor IX, ceredase, cerezyme and analogues, agonists and antagonists thereof.  
     
     
         29 . The device of  claim 23  wherein the active agent formulation is a powder and wherein the device is adapted to aerosolize the active agent formulation.  
     
     
         30 . The device of  claim 23  wherein the active agent formulation is contained in a blister and wherein the device is adapted to receive the blister.  
     
     
         31 . The device of  claim 23  wherein the device is adapted to aerosolize a powder active agent formulation.  
     
     
         32 . The device of  claim 31  wherein the device is adapted to aerosolize the powder active agent formulation using compressed air.  
     
     
         33 . A device for delivering an aerosolized active agent to the lungs of a human patient, wherein said device is adapted to deliver an aerosolized active agent formulation at an inspiratory flow rate of less than 17 liters per minute, wherein the device is adapted to aerosolize the active agent formulation and wherein the active agent formulation is (i) a powder, (ii) a solution, suspension, or slurry that may be nebulized, or (iii) suspended or dissolved in a propellant.  
     
     
         34 . The device of  claim 33  wherein the device is adapted to be used with an aerosolized active agent formulation in dry powder form.  
     
     
         35 . The device of  claim 33  wherein the device is adapted to deliver the aerosolized active agent formulation at an inspiratory flow rate of 10 liters per minute or less.  
     
     
         36 . The device of  claim 33  wherein the active agent formulation is a powder and wherein the device is adapted to aerosolize the active agent formulation.  
     
     
         37 . The device of  claim 33  wherein the active agent formulation is contained in a blister and wherein the device is adapted to receive the blister.  
     
     
         38 . A device for delivering aerosolized insulin to the lungs of a human patient, wherein said device comprises a flow restrictor to restrict an inspiratory flow rate of an aerosolized insulin formulation to less than 17 liters per minute and wherein the device is adapted to aerosolize the insulin.  
     
     
         39 . The device of  claim 38  wherein the inspiratory flow rate is 10 liters per minute or less.  
     
     
         40 . The device of  claim 38  wherein the active agent formulation is a powder and wherein the device is adapted to aerosolize the active agent formulation.  
     
     
         41 . The device of  claim 38  wherein the active agent formulation is contained in a blister and wherein the device is adapted to receive the blister.  
     
     
         42 . A device for delivering an aerosolized active agent to the lungs of a human patient, wherein said device comprises one or more orifices sized so that au aerosolized active agent formulation may be delivered at an inspiratory flow rate of less than 17 liters per minute, wherein the device is adapted to aerosolize the active agent formulation and wherein the active agent formulation is (i) a powder, (ii) a solution, suspension, or slurry that may be nebulized, or (iii) suspended or dissolved in a propellant.  
     
     
         43 . The device of  claim 42  wherein the device is adapted to deliver an aerosolized insulin formulation to the lungs.  
     
     
         44 . The device of  claim 42  wherein the orifices are sized so that the aerosolized active agent formulation may be delivered at an inspiratory flow rate of 10 liters per minute or less.  
     
     
         45 . The device of  claim 42  wherein the active agent formulation is a powder and wherein the device is adapted to aerosolize the active agent formulation.  
     
     
         46 . The device of  claim 42  wherein the active agent formulation is contained in a blister and wherein the device is adapted to receive the blister.  
     
     
         47 . A device for delivering an aerosolized active agent to the lungs of a human patient, said device comprising: 
 a chamber in flow communication with a mouthpiece;    means for aerosolizing the active agent; and    means for limiting an inspiratory flow rate through the mouthpiece to less than 17 liters per minute,    whereby an aerosolized active agent formulation in the chamber may be delivered to the human patient, the active agent formulation being (i) a powder, (ii) a solution, suspension, or slurry that may be nebulized, or (iii) suspended or dissolved in a propellant.    
     
     
         48 . The device of  claim 47  wherein the inspiratory flow rate is limited to 10 liters per minute or less.  
     
     
         49 . The device of  claim 47  wherein the device is adapted to deliver an aerosolized insulin formulation to the lungs.  
     
     
         50 . The device of  claim 47  further comprising means for aerosolizing the active agent.  
     
     
         51 . The device of  claim 47  wherein the active agent formulation is a powder and wherein the device is adapted to aerosolize the active agent formulation.  
     
     
         52 . The device of  claim 47  wherein the active agent formulation is contained in a blister and wherein the device is adapted to receive the blister.